GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (MEX:BIIB) » Definitions » Cyclically Adjusted PS Ratio

Biogen (MEX:BIIB) Cyclically Adjusted PS Ratio : 3.41 (As of Jul. 15, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Biogen Cyclically Adjusted PS Ratio?

As of today (2024-07-15), Biogen's current share price is MXN4250.00. Biogen's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was MXN1,247.42. Biogen's Cyclically Adjusted PS Ratio for today is 3.41.

The historical rank and industry rank for Biogen's Cyclically Adjusted PS Ratio or its related term are showing as below:

MEX:BIIB' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 2.55   Med: 7.87   Max: 22.51
Current: 3.01

During the past years, Biogen's highest Cyclically Adjusted PS Ratio was 22.51. The lowest was 2.55. And the median was 7.87.

MEX:BIIB's Cyclically Adjusted PS Ratio is ranked worse than
65.49% of 736 companies
in the Drug Manufacturers industry
Industry Median: 2.1 vs MEX:BIIB: 3.01

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Biogen's adjusted revenue per share data for the three months ended in Mar. 2024 was MXN260.546. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is MXN1,247.42 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Biogen Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Biogen's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Cyclically Adjusted PS Ratio Chart

Biogen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.44 4.63 3.91 4.00 3.47

Biogen Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.89 3.91 3.46 3.47 2.82

Competitive Comparison of Biogen's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - General subindustry, Biogen's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biogen's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biogen's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Biogen's Cyclically Adjusted PS Ratio falls into.



Biogen Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Biogen's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=4250.00/1247.42
=3.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biogen's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Biogen's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=260.546/131.7762*131.7762
=260.546

Current CPI (Mar. 2024) = 131.7762.

Biogen Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 132.287 100.560 173.353
201409 142.300 100.428 186.719
201412 164.724 99.070 219.105
201503 165.320 99.621 218.681
201506 172.526 100.684 225.804
201509 201.810 100.392 264.900
201512 221.213 99.792 292.113
201603 214.041 100.470 280.735
201606 243.956 101.688 316.139
201609 260.492 101.861 336.995
201612 272.866 101.863 352.997
201703 245.126 102.862 314.030
201706 262.230 103.349 334.359
201709 263.720 104.136 333.719
201712 306.213 104.011 387.955
201803 268.704 105.290 336.299
201806 318.155 106.317 394.343
201809 318.606 106.507 394.198
201812 345.849 105.998 429.958
201903 343.630 107.251 422.210
201906 364.878 108.070 444.920
201909 385.848 108.329 469.361
201912 388.774 108.420 472.525
202003 478.754 108.902 579.316
202006 528.148 108.767 639.874
202009 474.437 109.815 569.317
202012 368.228 109.897 441.539
202103 361.576 111.754 426.356
202106 368.016 114.631 423.058
202109 384.520 115.734 437.818
202112 380.211 117.630 425.937
202203 341.536 121.301 371.030
202206 356.276 125.017 375.539
202209 348.470 125.227 366.696
202212 341.113 125.222 358.968
202303 305.755 127.348 316.387
202306 289.384 128.729 296.235
202309 304.386 129.860 308.879
202312 277.626 129.419 282.682
202403 260.546 131.776 260.546

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Biogen  (MEX:BIIB) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Biogen Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Biogen's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (MEX:BIIB) Business Description

Industry
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.

Biogen (MEX:BIIB) Headlines

From GuruFocus

Q1 2023 Biogen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q2 2022 Biogen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q4 2021 Biogen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q3 2023 Biogen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Biogen Inc Investor Day Transcript

By GuruFocus Research 01-22-2024

Q3 2022 Biogen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q2 2023 Biogen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Biogen Inc at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 01-22-2024